InVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar)

Clone Catalog # Category
Zolbetuximab SIM0026
USD 224 - USD 7752

About InVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Zolbetuximab making it ideal for research use. This Zolbetuximab biosimilar antibody reacts with isoform 2 of human claudin 18. Claudin 18.2, a member of the claudin family, is commonly expressed in multiple cancers, including gastric and pancreatic cancer. Claudin 18.2 is not expressed in any healthy tissues except for gastric mucosa. Claudins play a major role in tight junctions which establish the paracellular barrier that controls the flow of molecules in the intercellular space between the cells of an epithelium. They also play an important role in tumorigenesis and inflammation. Alterations in claudin expression have been shown to lead to impaired functions of tight junctions, influence signaling pathways, and act as tumor promoting events in some epithelial cancers. In a humanized mouse model of prostate cancer Zolbetuximab demonstrated antitumor activity by stimulating ADCC and/or CDC.

InVivoSIM anti-human Claudin 18.2 (Zolbetuximab Biosimilar) Specifications

IsotypeHuman IgG1, κ
ImmunogenHuman claudin 18.2
Reported ApplicationsFunctional assays
FormulationPBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay
Aggregation<5% Determined by SEC
Purity>95% Determined by SDS-PAGE
Sterility0.2 μm filtration
ProductionPurified from cell culture supernatant in an animal-free facility
PurificationProtein A
Molecular Weight150 kDa
StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.